Indrajit Sinha, PhD, MBA
Dr. Indrajit Sinha brings over 30 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, Intellectual Property, technology transfer, and biopharmaceutical compliance. His work has been extensively published in highly reputed peer-reviewed journals. Through his passion for utilizing underappreciated technologies and applying them in innovative ways to achieve previously unattainable outcomes, he has created various intellectual property linked business opportunities since 2000.
In 2001, Dr. Sinha founded Medhospital Inc. Medhospital’s vision was to simplify the complex language and terminologies of healthcare and biomedicine to empower families in understanding and managing their health needs better. In 2011, he founded Biomedcore Inc. where he developed and patented a unique protocol that effectively enables accelerated individualized prediction of cancer progression and response to treatment. This technology has been grant
ed a patent in multiple jurisdictions and is being validated for clinical utility. Through a partnership with Suntrition Inc., a Natural Health Product manufacturing company, he evolved the company into a unique health solutions company, Acenzia Inc. Acenzia built a certified facility that seamlessly coordinated diagnostics and manufacturing services to the health and dietary supplement industry under one roof. Acenzia was sold to Novo Integrated Sciences Inc. in 2021.
Dr. Sinha has been actively involved in technology start-ups and investment communities for more than ten years. He has advised and evaluated companies through Ontario Centers of Innovations (OCI) and has successfully raised fundings from OCI, the Natural Sciences and Engineering Research Council of Canada (NSERC), MITACS (empowers Canadian innovation through effective partnerships), Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA), FedDev Ontario, and the National Research Council of Canada (NRC). Given the nature of projects he is involved in, Dr. Sinha also helps companies file for Scientific Research and Experimental Development (SR&ED) tax incentives in Canada.
Education
- 2021-2023
Executive MBA from the University of Cumbria, UK - 2008-2010
Post-doctoral, Wayne State University and Karmanos Cancer Institute in Detroit Michigan, USA - 2001-2007
Post-doctoral, National University of Singapore and the Agency for Science, Technology and Research (A*STAR), Singapore - 1995-2000
PhD in Microbiology, Delhi University, India - 1995-2000
MSc in Biotechnology, MS University of Baroda, India
Experience
Vice President, Science and Technology, Clinical Consultants International, USA (2023-Present)
• Clinical Consultants International was established initially as a hospital consulting firm.
• Eventually evolved into commercialization of pharmaceuticals, clinical trials and approvals of medical devices, research and regulatory support, and marketing and collaboration in the American healthcare system.
• Overlooking the preparedness of foreign companies for US-FDA and Health Canada. Helping companies define appropriate entry strategy for North American markets.
President, Kashbon Group Inc., Windsor, Ontario, Canada (2021-Present)
• Kashbon Group’s efforts are towards advancing life science products for commercial success. Its core focus is on therapeutics, consumer health products, food products, and medical devices.
• Its Consulting arm provides R&D and regulatory support to companies for penetrating the Canadian, Indian and the American markets.
Chief Science Officer, Novo Integrated Sciences Inc. (NVOS), USA and Canada (2021 - 2023)
• Novo Integrated Sciences is transforming healthcare.
• Overlooked the scientific and technological innovations, Quality/ Compliance and the Regulatory Affairs of the entire company.
• Ongoing consulting agreement with Novo Integrated Sciences and representing the company when needed as Chief Science Officer.
Chairman, EAST, New Delhi, India (2018-Present)
• Institute for Empowerment by Arts Science and Technology (IEAST) is a non-profit research and development centre that brings the most advanced research out of the laboratory to empower humanity.
• EAST has developed numerous agricultural products and health enhancing solutions that have impacted thousands of people.
• Its innovations range from germ-free tissue culture-raised plantlets, biofertilizers, biopesticides, bio-decomposers and renewable energy sources for agriculture, to antiviral disinfectants and nutritional solutions for human health.
Co-Founder and Co-President, Acenzia Inc., Windsor, Ontario, Canada (2018 - 2021)
• Stepped in as Co-President of Acenzia to reshape and restructure the company culture.
• Acenzia had an unsuccessful merger with Eureka93 that resulted in huge financial losses. Successfully unwound the transaction and started rebuilding Acenzia.
• Refocused the company and created the next five years vision.
• Developed new connections and started to look for new financial and strategic business partners.
• Strategically started hand sanitizer manufacturing during COVID19 to overcome business uncertainties. Acenzia was the first company regionally to get fully licensed for producing hand sanitizers under Health Canada and the US-FDA.
• Acenzia successfully merged with a new strategic partner, Novo Integrated Sciences Inc. in 2021. Co-Founder and Chief Scientific Officer 2015 - 2018 Acenzia Inc., Tecumseh, Ontario, Canada
• Acenzia was born out of the strategic merger between Biomedcore and Suntrition.
• Using the unique capabilities of individualized diagnostics along with unique proprietary manufacturing capabilities, Acenzia offered unparalleled research, product development and manufacturing services to pharmaceutical and nutraceutical industries globally.
• Testing for the efficacy of nutritional products on the conditions they are meant to support, is a break through that will assist science based brands to be market leaders.
• “Powered by Acenzia” is a brand that captures the essence of what Acenzia is all about.
• My responsibilities as a CSO involved overseeing the quality, compliance and regulatory affairs of the manufacturing along with research, development and innovation of Natural Health Products.
• Was involved in the implementation of Current Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP) with special focus on FDA 21 CFR Part 111, Health Products and Food Branch Inspectorate (HPFBI), and International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines and regulations. Acenzia’s manufacturing and testing facilities are certified under NSF International, GMP for Sport.
• Developed a fully compliant Level II laboratory with certifications from NSF, Public Health Agency (PHA) of Canada, Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA).
• Worked very closely with both OMAFRA and National Research Council (NRC) of Canada for full support and oversight of the ongoing zebrafish research.
Member of Expert Reviewer Panel, Ontario Centres of Innovation Inc. (Formerly OCE), Toronto, Ontario, Canada (2014 - Present)
• Responsibilities involve reviewing and recommending start-up company project proposals for financial support. Mentor start-up companies that are in the healthcare space.
Adjunct Associate Professor, University of Windsor, Windsor, Ontario, Canada (2014 - 2022)
• Developed a zebrafish research lab in the University of Windsor, Ontario.
• Recipient of numerous academic awards in partnership with the University.
• Position involved mentoring a MITACS funded Masters-Ph.D. student since 2011, completed 2019.
Co-founder, My Living Body Inc., Tecumseh, Ontario, Canada (2013 - 2015)
• It was an alliance of like-minded companies for the advancement of individualized treatment through innovation and integration. This company eventually merged with Biomedcore and Suntrition to enable commercializations of its research and development capabilities during creation of Acenzia.
Chief Scientific Officer, Suntrition Inc., Tecumseh, Ontario, Canada (2012 - 2015)
• Suntrition was a leader in small-batch, oral-dose manufacturing.
• Responsibilities as a CSO involved overseeing the quality, compliance and regulatory affairs of the manufacturing along with research, development and innovation of Natural Health Products. • Developed, evolved and maintained a compliant and certified facility under Health Canada, US-FDA, NSF-GMP for Sport, Halal, Kosher and United States Department of Agriculture’s National Organic Program (NOP).
• Each year between 2012 and 2015, PROFIT 200 & 500 has recognized Acenzia as one of the fastest growing companies in Canada.
Founder and CEO, Biomedcore Inc., Windsor, Ontario, Canada (2011 - 2015)
• Biomedcore has developed an in vivo immune-competent 3D tumour model that maintains the biology of the patient's tumour tissues and retains all propensities to develop and manifest characteristics of advanced clinical disease.
• Technology effectively predicts each patient's cancer relapse including the developing tumours drug sensitivity prior to treatment. It is currently being developed as an IVD for guiding individualized therapy in future.
Research Associate / Postdoctoral, Karmanos Cancer Institute (KCI), Wayne State University (WSU) Detroit, Michigan, USA (2008 - 2011)
• First to demonstrate that E3 ligase Itch and deubiquitinase Cyld act together to regulate inflammation.
• Developed new drug delivery strategies using nanoparticles and dendrimers and testing their efficacy in vitro in chronic and persistent infection models (Chlamydia). This technology is under commercialization.
Research Fellow / Postdoctoral, Institute of Molecular and Cell Biology (IMCB), Singapore (2001 - 2007)
• First to demonstrate the role of septins in regulating polarity in yeast; a process that is essential for hyphae formation - a key determinant of pathogenesis.
• First to monitor dynamic phosphorylation states of Cdc5 Polo-kinase to elucidate APC activity in DNA-damaged cells.
• Developed the first Candida mutant strain (IS89) expressing CaCdc28as, a mutated CaCdc28 sensitive to the ATP analog 1NM-PP1 (cdc28∆/cdc28F85G) – an effective tool for study of the regulation of cyclins.
• Published the first dormancy-dependent phosphorylation profile for M. bovis BCG that has diagnostic potential.
• Intellectual Property development and technology transfer/commercialization in the areas of biomedical research, drug development and medical devices.
Founder and President, Medhospital Foundation, New Delhi, India (2000 - Present)
• Medhospital Foundation's purpose is to promote health awareness and medical knowledge in the simplest language possible not neglecting the precision required to present the subject. This organization is under complete re-development.
Attachment Research and Training Staff, Pasteur Institute, Kolkata, India (1999 - 1999)
• Performed histopathology studies and monitored progression of Yersinia enterocolitica infection.
• Given hands-on training to a group of 20 medical students.
Attachment Research and Training Staff, Calcutta National Medical College, Kolkata, India (1999 - 1999)
• Involved in teaching clinical infection and serological response to Yersinia enterocolitica in mice.
Junior Research Fellow, University of Delhi, New Delhi, India (1996 - 2001)
• Simplified the identification of Yersinia enterocolitica from environmental samples.
• Demonstrated for the first time the pathogenic potential of environmental isolates of medically important bacteria of fecal origin, and the demographic prevalence of Y. enterocolitica.
• Worked in collaboration with Pasteur Institute Yersinia Research Unit, Pasteur Institute, France. • Worked and trained two Ph.D. students and a Master’s Student.
Project Fellow, University of Delhi, New Delhi, India (1995-1996)
• Demonstrated the ecological prevalence and health implications of medically important bacteria in wastewater and their implications in water treatment strategies.
• Coordinated a multi-disciplinary team of 15 people and collaboratively worked with 2 organizations, Ministry of Environment and Forests and University of Delhi, New Delhi, India.
Researcher, Masters in Biotechnology, MS University of Baroda, Vadodara, India (1993 - 1995)
• Discovered the importance of an anchor protein in the interaction between B. thuringiensis delta-toxin and H. armigera larval midgut receptors.
• Clinical Consultants International was established initially as a hospital consulting firm.
• Eventually evolved into commercialization of pharmaceuticals, clinical trials and approvals of medical devices, research and regulatory support, and marketing and collaboration in the American healthcare system.
• Overlooking the preparedness of foreign companies for US-FDA and Health Canada. Helping companies define appropriate entry strategy for North American markets.
President, Kashbon Group Inc., Windsor, Ontario, Canada (2021-Present)
• Kashbon Group’s efforts are towards advancing life science products for commercial success. Its core focus is on therapeutics, consumer health products, food products, and medical devices.
• Its Consulting arm provides R&D and regulatory support to companies for penetrating the Canadian, Indian and the American markets.
Chief Science Officer, Novo Integrated Sciences Inc. (NVOS), USA and Canada (2021 - 2023)
• Novo Integrated Sciences is transforming healthcare.
• Overlooked the scientific and technological innovations, Quality/ Compliance and the Regulatory Affairs of the entire company.
• Ongoing consulting agreement with Novo Integrated Sciences and representing the company when needed as Chief Science Officer.
Chairman, EAST, New Delhi, India (2018-Present)
• Institute for Empowerment by Arts Science and Technology (IEAST) is a non-profit research and development centre that brings the most advanced research out of the laboratory to empower humanity.
• EAST has developed numerous agricultural products and health enhancing solutions that have impacted thousands of people.
• Its innovations range from germ-free tissue culture-raised plantlets, biofertilizers, biopesticides, bio-decomposers and renewable energy sources for agriculture, to antiviral disinfectants and nutritional solutions for human health.
Co-Founder and Co-President, Acenzia Inc., Windsor, Ontario, Canada (2018 - 2021)
• Stepped in as Co-President of Acenzia to reshape and restructure the company culture.
• Acenzia had an unsuccessful merger with Eureka93 that resulted in huge financial losses. Successfully unwound the transaction and started rebuilding Acenzia.
• Refocused the company and created the next five years vision.
• Developed new connections and started to look for new financial and strategic business partners.
• Strategically started hand sanitizer manufacturing during COVID19 to overcome business uncertainties. Acenzia was the first company regionally to get fully licensed for producing hand sanitizers under Health Canada and the US-FDA.
• Acenzia successfully merged with a new strategic partner, Novo Integrated Sciences Inc. in 2021. Co-Founder and Chief Scientific Officer 2015 - 2018 Acenzia Inc., Tecumseh, Ontario, Canada
• Acenzia was born out of the strategic merger between Biomedcore and Suntrition.
• Using the unique capabilities of individualized diagnostics along with unique proprietary manufacturing capabilities, Acenzia offered unparalleled research, product development and manufacturing services to pharmaceutical and nutraceutical industries globally.
• Testing for the efficacy of nutritional products on the conditions they are meant to support, is a break through that will assist science based brands to be market leaders.
• “Powered by Acenzia” is a brand that captures the essence of what Acenzia is all about.
• My responsibilities as a CSO involved overseeing the quality, compliance and regulatory affairs of the manufacturing along with research, development and innovation of Natural Health Products.
• Was involved in the implementation of Current Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP) with special focus on FDA 21 CFR Part 111, Health Products and Food Branch Inspectorate (HPFBI), and International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines and regulations. Acenzia’s manufacturing and testing facilities are certified under NSF International, GMP for Sport.
• Developed a fully compliant Level II laboratory with certifications from NSF, Public Health Agency (PHA) of Canada, Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA).
• Worked very closely with both OMAFRA and National Research Council (NRC) of Canada for full support and oversight of the ongoing zebrafish research.
Member of Expert Reviewer Panel, Ontario Centres of Innovation Inc. (Formerly OCE), Toronto, Ontario, Canada (2014 - Present)
• Responsibilities involve reviewing and recommending start-up company project proposals for financial support. Mentor start-up companies that are in the healthcare space.
Adjunct Associate Professor, University of Windsor, Windsor, Ontario, Canada (2014 - 2022)
• Developed a zebrafish research lab in the University of Windsor, Ontario.
• Recipient of numerous academic awards in partnership with the University.
• Position involved mentoring a MITACS funded Masters-Ph.D. student since 2011, completed 2019.
Co-founder, My Living Body Inc., Tecumseh, Ontario, Canada (2013 - 2015)
• It was an alliance of like-minded companies for the advancement of individualized treatment through innovation and integration. This company eventually merged with Biomedcore and Suntrition to enable commercializations of its research and development capabilities during creation of Acenzia.
Chief Scientific Officer, Suntrition Inc., Tecumseh, Ontario, Canada (2012 - 2015)
• Suntrition was a leader in small-batch, oral-dose manufacturing.
• Responsibilities as a CSO involved overseeing the quality, compliance and regulatory affairs of the manufacturing along with research, development and innovation of Natural Health Products. • Developed, evolved and maintained a compliant and certified facility under Health Canada, US-FDA, NSF-GMP for Sport, Halal, Kosher and United States Department of Agriculture’s National Organic Program (NOP).
• Each year between 2012 and 2015, PROFIT 200 & 500 has recognized Acenzia as one of the fastest growing companies in Canada.
Founder and CEO, Biomedcore Inc., Windsor, Ontario, Canada (2011 - 2015)
• Biomedcore has developed an in vivo immune-competent 3D tumour model that maintains the biology of the patient's tumour tissues and retains all propensities to develop and manifest characteristics of advanced clinical disease.
• Technology effectively predicts each patient's cancer relapse including the developing tumours drug sensitivity prior to treatment. It is currently being developed as an IVD for guiding individualized therapy in future.
Research Associate / Postdoctoral, Karmanos Cancer Institute (KCI), Wayne State University (WSU) Detroit, Michigan, USA (2008 - 2011)
• First to demonstrate that E3 ligase Itch and deubiquitinase Cyld act together to regulate inflammation.
• Developed new drug delivery strategies using nanoparticles and dendrimers and testing their efficacy in vitro in chronic and persistent infection models (Chlamydia). This technology is under commercialization.
Research Fellow / Postdoctoral, Institute of Molecular and Cell Biology (IMCB), Singapore (2001 - 2007)
• First to demonstrate the role of septins in regulating polarity in yeast; a process that is essential for hyphae formation - a key determinant of pathogenesis.
• First to monitor dynamic phosphorylation states of Cdc5 Polo-kinase to elucidate APC activity in DNA-damaged cells.
• Developed the first Candida mutant strain (IS89) expressing CaCdc28as, a mutated CaCdc28 sensitive to the ATP analog 1NM-PP1 (cdc28∆/cdc28F85G) – an effective tool for study of the regulation of cyclins.
• Published the first dormancy-dependent phosphorylation profile for M. bovis BCG that has diagnostic potential.
• Intellectual Property development and technology transfer/commercialization in the areas of biomedical research, drug development and medical devices.
Founder and President, Medhospital Foundation, New Delhi, India (2000 - Present)
• Medhospital Foundation's purpose is to promote health awareness and medical knowledge in the simplest language possible not neglecting the precision required to present the subject. This organization is under complete re-development.
Attachment Research and Training Staff, Pasteur Institute, Kolkata, India (1999 - 1999)
• Performed histopathology studies and monitored progression of Yersinia enterocolitica infection.
• Given hands-on training to a group of 20 medical students.
Attachment Research and Training Staff, Calcutta National Medical College, Kolkata, India (1999 - 1999)
• Involved in teaching clinical infection and serological response to Yersinia enterocolitica in mice.
Junior Research Fellow, University of Delhi, New Delhi, India (1996 - 2001)
• Simplified the identification of Yersinia enterocolitica from environmental samples.
• Demonstrated for the first time the pathogenic potential of environmental isolates of medically important bacteria of fecal origin, and the demographic prevalence of Y. enterocolitica.
• Worked in collaboration with Pasteur Institute Yersinia Research Unit, Pasteur Institute, France. • Worked and trained two Ph.D. students and a Master’s Student.
Project Fellow, University of Delhi, New Delhi, India (1995-1996)
• Demonstrated the ecological prevalence and health implications of medically important bacteria in wastewater and their implications in water treatment strategies.
• Coordinated a multi-disciplinary team of 15 people and collaboratively worked with 2 organizations, Ministry of Environment and Forests and University of Delhi, New Delhi, India.
Researcher, Masters in Biotechnology, MS University of Baroda, Vadodara, India (1993 - 1995)
• Discovered the importance of an anchor protein in the interaction between B. thuringiensis delta-toxin and H. armigera larval midgut receptors.
Teaching Experience
- Supervised M.Sc./Ph.D. candidate as an external advisor 2011 - 2022 University of Windsor, ON, Canada.
- Supervised attachment students and Ph.D. students 2008 - 2010 School of Medicine, WSU and KCI, MI, USA.
- Coordinator for several terms 2003 - 2007 A*STAR-Students Outreach Program in IMCB, Singapore.
- Trained undergraduate students 2001 - 2007 Institute of Molecular and Cell Biology, Singapore.
- Teaching assistant 1996 - 1998 Dept. of Microbiology, University of Delhi, India.
- Attachment Research and training staff 1999 - 1999 At the Pasteur Institute as well as Calcutta Medical College, Kolkata, India.
Honours and Awards
- 2016: Phil Marder Award, GLIIFCA Scientific meeting, Michigan, USA
- 2013-2016: Technology Innovation Feasibility Project (TIFP), National Research Council of Canada, IRAP
- 2013: Research Tools and Instruments (RTI), Natural Sciences and Engineering Research Council of Canada, 2012-2013: Technical Problem Solving (TPS), Ontario Centres of Excellence (OCE)
- 2012-2013: Applied Research and Commercialization (ARC), FedDev Ontario
- 2012-2013: VentureStart, FedDev Ontario
- 2011: Odette Project for Technology, Innovation and Commercialization (OPTIC), Ontario Ministry of Economic Development and Trade, The Windsor Essex Economic Development Corporation and the Odette School of Business.
- 2000-2001: Research Fellowship, Department of Science and Technology, New Delhi, India.
- 1996-2000: Research Fellowship, University Grants Commission, New Delhi, India.
- 1995-1996: Research Fellowship, Ministry of Environment and Forests, New Delhi, India.
- 1993-1995: Student Scholarship, Department of Biotechnology, New Delhi, India.
Publications
Patents
Peer Reviewed Research Papers
- Sinha, I.(2012). Accelerated prediction of cancer progression and response to treatment. (CA2893549, WO2014083555A1, US20150315546A1, EP2925890A4, JP2016501021A, CN105121657A.) Awarded in Singapore, Japan, India, USA, Canada and EU.
Peer Reviewed Research Papers
- Crozier, M., Tubman, J., Fifield, B-A., Ferraiuolo, R-M., Ritchie, J., Zuccato, K., Mailloux, E., Sinha, I., Hamm, C., Porter, L. (2022). Frequently used antiemetic agent dexamethasone enhances the metastatic behaviour of select breast cancer cells. PLoS ONE 17(9): e0274675.
- Wright III,R.E., Shahin,L., Gogineni,V., Hussain, Z., Naeem, A., Sadasivan, S., Sinha, I., Neely, M., Michellhaugh, S.K., Mittal, S., Joshee, N. and Parajuli, P. (2021). Scutellaria Extract Inhibits Proliferation and Migration of Brain- Metastatic Lung Cancer Cells via Regulation of Multiple Signaling Pathways J. Medicin. Activ. Plant. 10:32-41.
- He Q., Au, B., Kulkarni, M., Shen, Y., Lim, K.J., Maimati, J., Wong, C.K., Luijten, M.N.H., Chong, H.C., Lim, E.H., Rancati, G., Sinha, I., Fu, Z., Wang, X., Connolly, J.E., Crasta, K. (2018). Chromosomal instability-induced senescence potentiates cell non-autonomous tumourigenic effects. Oncogenesis. 7: 62.
- Jakhar, R., Luijten, M.N.H., Wong, A.X.F., Cheng, B., Neo, S.P., Au, B., Kulkarni, M.D., Lim, K.J., Maimaiti, J., Chong, H.C., Lim, E.H., Tan, T.B.K., Ong, K.W., Sim, Y., Wong, J.S.L., Khoo, J.B.K., Ho, J.T.S., Guo, K., Chua, B.T., Sinha, I., Wang, X., Connolly, J.E., Gunaratne, J. And Crasta, K.C. (2018). Autophagy governs protumorigenic effects of mitotic slippage-induced senescence. Mol. Cancer Res. 16:1625-1640.
- Ferraiuolo, R-M., Tubman, J., Sinha, I., Hamm, C. and Porter, L. (2017). The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting Tamoxifen resistance. Oncotarget 8: 23337-23352.
- Tan, D.S.W., Haaland, B., Gan, J.M., Tham, S.C., Sinha, I., Tan, E.H., Lim, K.H., Takano, A., Krisna, S.S., Myint Thu, M.M., Liew, H.P., Ullrich, A., Lim, W.T. and Chua, B.T. (2014). Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer. Mol. Cancer. 13: 13.
- Venuprasad, K., Ahmed, N., Zeng, M., Polin, L. Sinha, I., Rathinam, C., Flavell, R. and Massoumi, R. (2013). The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. J. Immunol. 190: 170.10.
- Ahmed, N., Zeng, M., Sinha, I., Polin, L., Wei W-Z., Rathinam, C., Flavell, R., Massoumi, R. & Venuprasad, K. (2011) The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 2: 1176-1183.
- Zhang, T., Nirantar, S., Lim, H.H., Sinha, I. & Surana, U. (2009) DNA damage checkpoint maintains Cdh1 in an active state to inhibit anaphase progression. Dev. Cell 17: 541-551.
- Sinha, I., Wang, Y.M., Philp, R., Li, C.R., Yap, W.H. & Wang, Y. (2007) Cyclin-dependent kinases control septin phosphorylation in Candida albicans hyphal development. Dev. Cell 13: 421-432.
- Sinha, I. & Dick, T. (2004) Role of malonyl coenzyme A: Acyl carrier protein transacylase (MCAT) in the growth-inhibitory effect of the calmodulin antagonist trifluoperazine in Mycobacterium bovis BCG. J. Antimicrob. Chemother. 53: 1072-1075.
- Sinha, I., Boon, C. & Dick, T. (2003) Apparent growth phase-dependent phosphorylation of malonyl coenzyme A: Acyl carrier protein transacylase (MCAT), a major fatty acid synthase II component in Mycobacterium bovis BCG. FEMS Microbiol. Lett. 227: 141-147.
- Virdi, J.S., Sinha, I., Rajendran P. & Singh I. (2001) Arsenite-induced multiple antibiotic resistance phenotypes in environmental isolates of Yersinia enterocolitica. Curr. Microbiol. 43: 144-146.
- Sinha, I. & Virdi, J. S. (2000) Differentiation of non-pathogenic (biotype 1A) Yersinia enterocolitica from pathogenic bioserotypes by sodium acetate utilization. J. Med. Microbiol. 49: 674-676.
- Bansal, N., Sinha, I. & Virdi, J.S. (2000) Virulence plasmid (pYV)-associated susceptibility of Yersinia enterocolitica to chlorine and heavy metals. J. Appl.Microbiol. 89: 663-667.
- Bansal, N., Sinha, I. & Virdi, J.S. (2000) Arsenic and cadmium resistance in environmental isolates of Yersinia enterocolitica and Yersinia intermedia. Can. J. Microbiol. 46: 481-484.
- Sinha, I. & Virdi, J.S. (2000) In vitro antibiotic susceptibilities of Yersinia enterocolitica and Yersinia intermedia isolated from sewage effluents. Curr. Sci. 79: 90-92.
- Sinha, I. & Virdi, J.S. (2000) Isolation of Yersinia enterocolitica and Yersinia intermedia from wastewaters and their biochemical and serological characteristics. Curr. Sci. 2000, 79: 510-513.
Book Chapter
- Virdi, J.S., Sachdeva, S., Bhagat, N., Singh, I., Sinha, I., Sharma, S., Mallik, S., Mittal, S. (2005). Serological and molecular diversity of Yersinia enterocolitica isolated from India. In: Molecular diversity. Current perspectives and potential applications (Edited by T. Satyanarayana and B.N. Johri). Published by IK International Pvt. Ltd., New Delhi. pp. 1037-1052.
White Paper
- Li, F., Maimaiti, J., McConnell, C., Tubman, J., Porter, L., Sinha, I. and Lim K.J. (2018). Design and development of an antioxidant formulation with measurable effects against oxidative stress, infection induced inflammation, and vascular development during tumour induced angiogenesis.
Conference Presentations
- Sinha, I. (2017). A Rapid, In Vivo Zebrafish Model to Elucidate the Micrometastatic Potential of Human Lung Cancer Cells. Oral presentation at CYTO 2017 Scientific meeting, Boston, USA, Jun 10-15.
- Sinha, I. (2016). A Rapid, In Vivo Zebrafish Model to Elucidate the Micrometastatic Potential of Human Lung Cancer Cells. Oral presentation at GLIIFCA Scientific meeting, Michigan, USA.
- Tubman, J., Sinha, I. and Porter, LA. (2014). A role of Spy1 in breast cancer metastasis. Poster presentation at Cold Spring Harbour Mechanisms and Models of Cancer, Cold Spring Harbour, NY, Aug 29.
- Benchaala, I., Sinha, I., Hali, M., Gerard, H., Bharatwaj, B, Hudson., A., Rocha, S. and Whittum-Hudson, J. (2011). Reduction in Chlamydia trachomatis-associated murine reactive arthritis by novel peptide vaccine candidates. Oral presentation at ACR/ARHP Scientific meeting 11, Chicago, USA, Nov 5-9.
- Whittum-Hudson, J., Hali, M., Sinha, I., Bharatwaj, B., Oszust, C., Hudson, A. and da Rocha, S. (2011). Novel Mimotope Peptides as anti-chlamydial vaccine candidates. Poster presentation at 15th International Congress of Mucosal Immunology, Paris, France, July 5-9.
- Peng, D.J., Sinha, I., Zeng, M., Subramaniam, M., Spelsberg, T.C. and Venuprasad, K. (2010). Non-canonical K-27 linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. Poster presentation at 39th Autumn Immunology Conference, Chicago, IL, USA, Nov. 19-22.
- Bonneau, P., Macpharlin, C., Hali, M., Benchaala, I., Sinha, I., Kannan, R., Mishra, M. and Whittum-Hudson, J. (2010). Characterizing Therapeutic Effects of Antibiotic-loaded Nanodevices in Chlamydial Infections. Medical student summer research symposium, Chemical Engineering & Materials Science, College of Engineering, Wayne State University, Detroit, USA.
- Mishra, M.K., Kotta, K., Benchaala, I., Wykes, S.M., Hali, M., Sinha, I., Whittum-Hudson, J. and Kannan, R.M. (2009) Development of Folate-PAMAM and Azithromycin-PAMAM Nanodevices for Biodistribution, Imaging, Cellular Uptake, and Targeted Delivery to Chlamydial Infections. Poster presentation at AIChE Annual Meeting, Nashville, TN, USA, Nov. 8-13.
- Benchaala, I., Sinha, I., Wykes, S.M., Hali, M., Mishra, M., Kotta, K., Kannan, R.M., Whittum-Hudson, J.A. (2009) Targeted delivery of Nanoparticles to Chlamydia trachomatis–infected tissues in murine reactive arthritis. Oral presentation at ACR/ARHP Scientific meeting 09, Philadelphia, Pennsylvania, USA, Oct 17-21.
- Mishra, M.K., Kotta, K., Benchaala, I., Wykes, S., Hali, M., Sinha, I., Whittum-Hudson, J. and Kannan, R.M. (2009) Development of PAMAM-dendrimer based nanodevices for targeted delivery to Chlamydia trachomatis infection. Poster presentation at Nanoscience: Challenges for the Future: 237th ACS National Meeting & Exposition, Salt Lake City, UT, Mar. 22-26.
- Sinha, I., Oszust, C., Sekhon, K., Wu, L. Hali, M., da Rocha, S., Hudson, A., Whittum-Hudson, J. (2009) Test of novel peptides as anti-chlamydial vaccine candidates. Oral presentation at CBRS 2009: 4th Biennial Meeting of the Chlamydia Basic Research Society, Little Rock, Arkansas, USA, Mar. 20-23.
- Whittum-Hudson, J., Benchaala, I., Wykes, S., Hali, M., Sinha, I., Mishra, M., Kotta, K., Kannan, R.M. (2009) Development of PAMAM-dendrimer based nanodevices for targeted delivery to Chlamydia trachomatis infection. Poster presentation at CBRS 2009: 4th Biennial Meeting of the Chlamydia Basic Research Society, Little Rock, Arkansas, USA, Mar. 20-23.
- Sekhon, K., Wykes, S., Sovinski, A., Toti, U., Hali, M., Sinha, I., Gérard, H., Hudson, A., Panyam, J., Whittum-Hudson, J. (2009) Use of nanotechnology to target acutely and persistently Chlamydia-infected cells for therapy and imaging in vitro and in vivo. Poster presented at CBRS 2009: 4th Biennial Meeting of the Chlamydia Basic Research Society, Little Rock, Arkansas, USA, Mar. 20-23.
- Sinha, I., Wang, Y.M., Philp, R., Li, C.R., Yap, W.H. and Wang, Y. (2008) Septin phosphorylation in Candida albicans during hyphal development. ASM Conferences: 9th Candida and Candidiasis, Jersey City, NJ, USA, Mar. 24-28.
- Sinha, I. and Dick, T. (2004) Role of malonyl coenzyme A: Acyl carrier protein transacylase (MCAT) in the growth-inhibitory effect of the calmodulin antagonist trifluoperazine in Mycobacterium bovis BCG. Oral presentation at NITD Inaugural Symposium on Dengue Fever and Tuberculosis, Singapore, Jul. 5-6.
- Sinha, I., Boon, C. and Dick, T. (2003) Growth phase-dependent Proteome phosphorylation in Mycobacterium bovis BCG. Poster presentation at the 103rd ASM conference, Washington DC, USA, May. 2003.
- Sinha, I., Boon, C. and Dick, T. (2003) Growth phase-dependent Proteome phosphorylation in Mycobacterium bovis BCG. Oral presentation at NITD Inaugural Symposium on Dengue Fever and Tuberculosis, Singapore, Jan. 22-23.
- Sinha, I., Boon C., and Dick, T. (2002) Growth phase-independent proteome phosphorylation in Mycobacterium bovis BCG. Oral presentation at the Second International Conference on Structural Biology and Functional Genomics, Singapore, Dec. 2-4.
- Sinha, I. and Virdi, J. S. (2000) Environmental Yersinia enterocolitica biotype 1A produce water-soluble siderophore(s) but lack yersiniophore. Oral presentation at 40th Annual Conference of AMI at Bhubaneswar, India. Jan. 22-24.
Publications
Patents